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Introduction: B-cell activation is pivotal in rheumatoid arthritis (RA) pathogenesis and
represents a relevant therapeutic target. The main aim of this study was to characterize
the profiles of B-cell factors and their decoy receptors in RA and evaluate their clinical
relevance.
Methods: sBLyS, sAPRIL, sBCMA, sTACI, sBLyS-R, and several cytokines’ serum
levels were measured by immunoassays in 104 RA patients and 33 healthy controls (HC).
An additional group of 42 systemic lupus erythematosus (SLE) patients were enrolled
as disease controls. Whole blood IFI44, IFI44L, IFI6, and MX1 gene expression was
measured and averaged into an IFN-score. BLyS membrane expression (mBLyS) was
assessed on blood cell subsets by flow cytometry.
Results: increased sAPRIL and sBCMA levels were found in RA, whereas BLyS was
elevated in very early RA (VERA). No differences were observed for sTACI and sBLyS-R.
An increased sBLyS/sBLyS-R ratio was associated with poor clinical outcome at 6 and
12 months in VERA, whereas a positive association with disease activity was observed
in established disease. Increased mBLyS expression was found on monocytes, mDCs,
neutrophils and B-cells in RA, to a similar extent that in SLE patients. Cluster analysis
identified a specific B-cell factors profile overrepresented in RA and associated with
autoantibodies, elevated proinflammatory cytokines (IFNα, MIP1α, TNFα, IL-37, and
GM-CSF) and increased type-I IFN signature. Increasing sBCMA and sBLyS serum levels
upon treatment and mBLyS expression at baseline on monocytes and mDCs, but not
B-cells, were associated with poor clinical outcome upon TNFα-blockade.
Conclusions: profound and complex alterations of soluble and membrane-bound
B-cell factors are observed in RA associated with clinical outcomes, thus supporting
its applicability to guide patient stratification along disease course.
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INTRODUCTION
As main orchestrators of the humoral immune response,
the role of B-cells in rheumatoid arthritis (RA) has been
largely investigated. Although classically considered as antibody-
producing cells, the B-cell compartment is now recognized to
be composed by different cell subsets at distinct differentiation
stages (1). Of note, B-cell depletion therapy revealed a differential
effect on distinct subsets and autoantibody levels, thus supporting
that the role for B-cells goes beyond autoantibody production
to include antigen presentation, T-cell activation and cytokine
production (2, 3). Therefore, the control of B-cell activation and
function is of pivotal relevance in RA pathogenesis.
B-cell activation is regulated by several members of the
Tumor Necrosis Factor (TNF) superfamily. This family includes
two closely related stimulating factors, BLyS (B Lymphocyte
Stimulating factor) and APRIL (A Proliferation-Inducing
Ligand), both central players of B-cell development and
homeostasis (4). Altered serum levels of these cytokines
have been found in immune-mediated rheumatic conditions (5).
These B-cell activating factors develop their cellular responses via
three different receptors: BCMA (B-cell Maturation Antigen),
TACI (Transmembrane Activator and CALM Interactor) or
BLyS-R (also known as BAFF receptor or BR3) (6). Recent
studies have found that these receptors are present in both
membrane-bound and soluble isoforms, as decoy receptors.
However, their role in pathogenesis is far from being clear.
Moreover, these receptors are able to bind the different B-
cell factors with different affinities (6–8), hence delineating a
complex network of regulatory mechanisms, with potential
different cytokine-receptor axes involved, underlying B-cell
activation. More importantly, different cell populations other
than B-cells have been reported to produce BLyS (9, 10). All these
lines of evidence support an intriguing biological complexity of
the B-cell factors network. Additionally, recent studies by our
group (11, 12) and others (13, 14) point toward a connection
between BLyS and type I IFN in systemic conditions. However,
although type I IFNs have been associated with clinical outcomes
in RA (15), including ACPA levels, whether a link between type I
IFN and B-cell factors exists in RA remains unknown.
B-cells, and B-cell activation, are attractive disease targets
and several strategies and specific drugs have been tested
in RA. Unfortunately, some of these drugs have shown a
moderate clinical efficacy in clinical trials [reviewed in (16)].
Such a complex regulation within the B-cell compartment, with
Abbreviations: ACPA, anti-citrullinated peptide antibodies; APRIL, A
Proliferation-Inducing Ligand; BCMA, B-cell Maturation Antigen; BLyS,
B Lymphocyte Stimulating factor; CRP, C-reactive protein; csDMARDs,
conventional synthetic DMARDs; DAS28, disease activity score 28-joints;
DMARDs, disease-modifying antirheumatic drugs; EULAR, European league
against rheumatism; ESR, erythrocyte sedimentation rate; HAQ, health assessment
questionnaire; HC, healthy controls; IFI6, interferon alpha inducible protein 6;
IFI44, interferon induced protein 44; IFI44L, interferon induced protein
44 like; IFN, interferon; IRG, interferon-responding gene; MHC, major
histocompatibility factor; MX1, MX dynamin like GTPase 1; NSAIDs, non-
steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid
factor; TACI, Transmembrane Activator and CALM Interactor; TNFα, tumor
necrosis factor alpha.
synergistic and redundant effects, could be a limitation for the
clinical efficacy of these therapies. However, a knowledge gap
exists regarding the broad picture of the B network depicted
by B-cell factors and their receptors in RA. Therefore, a better
understanding of the latter is crucial to ensure clinical efficacy
and the identification of biomarkers to predict clinical response.
We hypothesize that different patterns among B-cell factors
and their decoy receptors may be found in RA in association
with clinical features. The main aim of the present study is to
comprehensively analyse the network of B-cell factors in RA,
including their soluble and membrane-bound forms as well as
their decoy receptors, with a special focus on its clinical relevance
as potential biomarkers.
MATERIALS AND METHODS
Ethics Statement
The study protocol was approved by the Institutional Review
Board (Comité de Ética de Investigación Clínica del Principado
de Asturias, ref. PI16/00113) in compliance with the Declaration
of Helsinki. All study subjects gave written informed consent.
Patients and Controls
A total of 104 patients were recruited from the Department
of Rheumatology at Hospital Universitario Central de Asturias
(Spain). A complete clinical examination, including Disease
Activity Score 28-joints (DAS28) and HAQ calculations, was
performed on all patients during their clinical appointments.
Patients fulfilling the 2010 ACR/EULAR classification criteria
for rheumatoid arthritis with a disease duration longer than
6 months since diagnosis were classified as established RA (n
= 85). Patients recruited at disease diagnosis (i.e., the same
day that the definite diagnosis is set) were classified as very
early rheumatoid arthritis (VERA) patients (n = 19). VERA
patients were not previously exposed to any treatment and
all had a duration of symptoms below 18 weeks (mean ±
SD: 12.1 ± 5.0 weeks). These patients were prospectively
followed-up for 1 year, and clinical outcomes were registered
at 6 (T6) and 12 (T12) months. Clinical management was
performed according to EULAR recommendations (17) and
clinical response was evaluated by EULAR criteria (18). Patients
exhibiting a good response were considered as responders,
whereas those with moderate or no response were classified as
non-responders. Treatment adherence was monitored by our
internal procedures in our in-day hospital (bDMARDs) and
rheumatology department (csDMARDs). An additional group of
13 biological-naïve RA patients (12 women, age, median(range):
43(30–65), DAS28 5.08(1.93), 38.5% RF+, 46.1% ACPA+),
candidates for TNFα-blockade was prospectively followed-up for
3 months. A blood sample was obtained before and 3-months
after initiation of TNFα-blockade. Sample size calculation for this
group was performed to allow the identification of a difference of
1.2 points in the DAS28 score, with an a = 0.05 and a power of
0.80 in a paired design.
A group of 33 gender- and age-matched healthy volunteers
was simultaneously recruited as healthy controls (HC) from
the same population. An additional group of 42 systemic
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lupus erythematosus patients was recruited as disease controls
(Supplementary Table 1). SLE diagnosis was defined according
to the ACR revised criteria for SLE classification (19). A blood
sample was collected from all individuals by venipuncture. Fresh
blood was processed immediately for flow cytometry experiments
and RNA stabilization, and serum samples were frozen at−80◦C
until cytokine measurements.
Cytokine Quantification
Serum levels of circulating cytokines were analyzed by
commercial immunoassays following manufacturer instructions
as follows: sBLyS [Human BAFF instant ELISA, eBioscience,
detection limit (d.l.) = 0.13 ng/ml], sBCMA (TNFRSF17 ELISA
kit, Raybiotech, d.l. = 0.025 ng/ml), sTACI (Human TACI
ELISA kit, Raybiotech, d.l. = 0.32 pg/ml), sAPRIL (Human
APRIL Platinum ELISA, eBioscience, d.l.= 0.19 ng/ml), sBLyS-R
(Human TNFRSF13C, abcam, d.l. = 0.78 pg/ml), IL-10 (Human
IL-10 ELISA high sentivity, eBioscience, d.l. = 0.19 pg/ml),
IL-37 (Human IL-37/IL1F7 ELISA, BosterBio, d.l. = 4.8 pg/ml),
TNFα (Human TNFα Mini EDK, Peprotech, d.l. = 3.9 pg/ml)
and IFNg (IFNg OptEIA kit, BD Bioscience, d.l. = 0.58 pg/ml).
Levels of IFNα, MIP1α, IL-8 and GM-CSF were quantified using
a Cytometric Bead Array Flex Set (BD) in a FACS Canto II flow
cytometer. The detection limits were 1.25, 0.2, 1.2, and 0.2 pg/ml,
respectively.
IFN Score
An IFN score was calculated as previously described by our group
(15). Briefly, mRNA was isolated from whole blood and the gene
expression of IFI44, IFI44L, MX1 and IFI6 was evaluated with
TaqMan pre-designed assays by RT quantitative PCR. Expression
levels were evaluated by the 2−1t method, using the GAPDH
gene expression as housekeeping to normalize Ct values. The
expression levels were log-transformed. Z-scores were calculated
for each gene and an IFN score was calculated by averaging all
genes per individual.
Flow Cytometry
BLyS surface expression (mBLyS) was quantified in 35 RA
patients and 31 HC by flow cytometry on B-cells, neutrophils,
monocytes and mDCs as previously described (12) using
the following fluorescent-labeled antibodies: BLyS-FITC
(eBioscience), CD19-CF-Blue (Immunostep), CD14-APC-Cy7
(BioLegend), CD1c-APC (eBioscience), or fluorochrome-
matched control antibodies (all from eBioscence). Whole
blood cells were extracellularly stained with the appropriate
monoclonal antibodies or isotype controls for 30min at 4◦C.
Then, red blood cells were lysed and cells were washed twice with
PBS.
Then, cells were acquired and different leukocyte
subpopulations were identified according to the expression
of specific surface markers: mDCs (CD19-CD1c+), monocytes
(CD14+), B-cells (CD19+). Neutrophils were identified based
on their forward and side scatter signal. mBLyS expression was
calculated as the mean fluorescence intensity (MFI) of the gated
populations after subtracting the background signal from the
respective isotype control.
Statistical Analyses
Continuous variables were summarized as median (interquartile
range) or mean ± standard deviation. Categorical variables
were expressed as n(%). Differences among groups were
analyzed by Mann Withney U, Kruskal-Wallis (with Dunn-
Bonferroni correction for multiple comparisons) or χ2 tests,
as appropriate. Wilcoxon test was used for paired samples.
Correlations were assessed by Spearman ranks’ test. Cluster
analysis was performed using squared euclidean distances and
Ward’s Minimum Variance Method, in order to identify clusters
minimizing the loss of information (and minimize the effect
of different sample sizes among clusters). R package heatmap.2
was used to generate the heatmap for visualization purposes. A
p < 0.050 was considered as statistically significant. Statistical
analyses were performed in SPSS 22.0, R 3.3.1 and GraphPad
Prism 5.0. Sample size calculations and power analyses were
carried out in PS–Power and Sample Size Calculations v. 3.1.2
(Vanderbilt University, United States).
RESULTS
B-Cell Related Factors in RA: Differences
Between Very Early and Established
Disease
The serum levels of sAPRIL, sBLyS, sBCMA, sTACI, and
sBLyS-R were measured in 104 RA patients (including VERA
and established RA) and 33 HC (Table 1). RA patients exhibited
increased sAPRIL and sBCMA serum levels compared with HC,
whereas no differences were observed for sTACI and sBLyS-R
(Figure 1A). sBLyS was increased in VERA patients but not
in patients with established disease (Figure 1A). The sBLyS
levels in VERA were comparable, although slightly lower, to
those observed in SLE patients (Supplementary Figure 1A).
Interestingly, the sBLyS/sBLyS-R ratio was increased in
VERA (Figure 1B). However, DAS28 was positively correlated
to the sBLyS/sBLyS-R ratio (r = 0.298, p = 0.008) and
negatively with sTACI (r = −0.315, p = 0.004) in established
disease, but not in VERA. VERA patients were prospectively
followed for 1 year and DAS28 score and clinical response
to csDMARD treatment were registered. Of note, increased
sBLyS/sBLyS-R ratio at onset was associated with a poor
clinical response after 6 and 12 months (Figure 1C). No
differences were observed for the rest of the B-cell factors
analyzed.
Next, the associations between B-cell related factors and
the IFN score were analyzed. IFN score was increased in
VERA compared to HC and a greater increase was found
in patients with established disease (Figure 1D). Interestingly,
diverging associations were observed with the B-cell related
factors: IFN score was negatively associated with sBLyS-R
(r = −0.463, p = 0.031) in VERA patients, whereas it
was positively associated with sBLyS-R (r = 0.271, p =
0.029) and sTACI (r = 0.210, p = 0.050) in established
disease.
Finally, in order to shed new light into the BLyS production
in RA, mBLyS surface expression was analyzed in different
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TABLE 1 | Characteristics of the subjects recruited in this study.
HC
(n = 33)
RA
(n = 104)
p-value
DEMOGRAPHICAL FEATURES
Age, years; median (range) 49.16 (35.17–60.17) 54.37 (22.00–87.00) 0.104
Gender, f/m 25/8 85/19 0.452
DISEASE FEATURES
Disease duration, years; median (range) 3.83 (0.00–15.00)
Age at diagnosis, years; median (range) 49.37 (19.00–70.00)
Disease activity (DAS28) 3.77 (2.02)
Tender Joint Count 3.00 (7.00)
Swollen Joint Count 2.00 (5.00)
Patient Global Assessment (0-100) 45.00 (43.00)
ESR, mm/h 18.00 (23.00)
CRP, mg/l 2.22 (4.35)
6 HAQ (0-3) 1.00 (1.22)
RF (+), n (%) 60 (57.6)
ACPA (+), n (%) 67 (64.4)
Erosive disease, n (%) 40 (38.4)
TREATMENTSa, n (%)
Glucocorticoids 58 (67.4)
Methotrexate 65 (75.5)
TNFα blockers 32 (37.2)
Tocilizumab 3 (3.4)
CYTOKINES SERUM LEVELS, MEAN ± SD
TNFα, pg/ml 79.78 ± 99.25 303.44 ± 234.83 <0.001
IFNα, pg/ml 2.28 ± 8.00 30.40 ± 70.55 0.002
MIP1α, pg/ml 1.37 ± 3.91 27.49 ± 52.17 <0.001
GM-CSF, pg/ml 1.85 ± 4.42 41.51 ± 47.15 <0.001
IFNg, pg/ml 4.14 ± 2.87 9.26 ± 17.66 0.020
IL-8, pg/ml 26.81 ± 33.26 54.51 ± 34.87 0.010
IL-10, pg/ml 1.33 ± 0.63 3.72 ± 11.66 0.006
IL-37, pg/ml 358.17 ± 1187.19 501.15 ± 1207.99 0.954
IFN SCORE, MEAN ± SD
IFN score -0.68 ± 0.71 0.23 ± 0.86 <0.001
aTreatment usage was calculated as the number of patients using a given treatment among the number of patients receiving any treatment (n = 85).
cell populations. RA patients exhibited an increased mBLyS
expression on B-cells, neutrophils and, to a higher degree, on
monocytes andmDCs (Figure 1E). No differences were observed
between VERA and established RA. Both subsets of RA patients
exhibited a similar mBLyS upregulation than that of found in
SLE patients (Supplementary Figure 1B). Interestingly sTACI
negatively correlated mBLyS expression on monocytes (r =
−0.376, p = 0.037) and mDC (r = −0.465, p = 0.008) in HC,
but not in RA. However, sBCMA was negatively associated with
mBLyS expression on monocytes (r =−0.351, p= 0.030) in RA.
Overall, these results confirm that RA patients exhibit a
complex picture of altered levels of B-cell related factors and
decoy receptors, with important differences being found between
the early and established stages of the disease. Different immune
cell populations beyond B-cells, especially monocytes andmDCs,
may be associated with the network of B-cell factors.
B-Cell Factors Profiling in RA: Clinical and
Immunological Relevance
In order to gain additional insight into the complex network
of B-cell factors in RA, an integrative approach was performed.
Then, an unsupervised cluster analysis based on sBLyS, sAPRIL,
sBCMA, sTACI and sBLyS-R serum levels was conducted.
Cluster analysis identified 2 clusters (thereafter referred to as
I and II), cluster II being hallmarked by increased sAPRIL
and sBCMA levels (Figure 2). Cluster II was overrepresented
in RA compared to HC (32/104 vs. 3/33, p = 0.015).
Sample sizes were confirmed to be adequate to identify the
aforementioned clusters with the given frequencies at an
alfa= 0.05.
Interestingly, the different profiles of B-cell factors were
associated with clinical and immunological features in RA
(Table 2). Cluster II-RA patients showed increased RF and
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FIGURE 1 | B-cell related factors in RA patients according to disease duration stage. (A) Serum levels of B-cell related factors and their decoy receptors in HC and
RA patients classified as very early RA (VERA) or established RA (ERA). (B) Differences in the sBLyS/sBLyS-R ratio between HC, VERA and established RA patients.
(C) Analysis of the sBLyS/sBLyS-R ratio in VERA patients depending on their clinical outcome at 6 (T6) or 12 (T12) months since disease onset. Patients were
classified as responders (R) or non-responders (NR) according to EULAR criteria. (D) Analysis of the type I IFN score in HC and RA patients according to disease
duration stage. (E) Analysis of the BLyS surface expression (mBLyS) on B-cells, monocytes (MØ), neutrophils (NØ) and myeloid DC (mDC). No differences between
VERA and RA patients were observed. Hedges’g statistics were computed and added to the bottom of each graph to compare the size effect observed among cell
populations. Boxes represent 25th and 75th percentiles, whereas whiskers represent minimum and maximum values. Statistical analyses were performed by
Kruskal-Wallis with Dunn-Bonferroni tests for multiple comparisons (A–D) or Mann-Withney U tests (E). P-values shown correspond to those obtained in the
Dunn-Bonferroni tests (A–D) or Mann-Withney U-tests (E).
ACPA positivity and were more likely to be treated with
anti-TNFα agents compared to their cluster I-counterparts.
Additionally, higher IFNα, MIP1α, TNFα, IL-37, GM-CSF
serum levels, and IFN score were observed in patients of
the cluster II. Apart from differences in serum levels, cluster
II patients exhibited distinct associations of B-cell factors.
sBLyS was positively correlated with DAS28 in cluster II-
RA patients (r = 0.441, p = 0.013), but not in their
cluster I counterparts. Moreover, sAPRIL levels exhibited a
negative correlation with those of sBLyS-R (r = −0.463, p =
0.010) and sTACI (r = −0.411, p = 0.019) in cluster II-RA
patients.
All these results confirm that distinct subsets of RA patients
can be distinguished based on B-cell factors. RA patients
characterized by elevated sAPRIL and sBCMA levels exhibited
a higher prevalence of autoantibodies, increased type I IFN
activation and elevated levels of proinflammatory and immune-
stimulatory mediators despite being largely treated with anti-
TNFα agents.
B-Cell Factors Upon TNFα-Blockade:
Association With Clinical Outcome
Due to the association between the B-cell profile and anti-
TNFα usage, we decided to further investigate the changes in
B-cell factors serum levels upon anti-TNFα therapy and their
associations with the clinical response in a prospective study. To
this aim, the serum levels of B-cell factors and mBLyS expression
were evaluated in a group of 13 biological-naïve RA patients
at baseline (BL) and after 3 months upon TNFα-blockade (PT,
post-treatment).
No changes after treatment were observed in any of the B-cell
factors analyzed (sBCMA: p = 0.507, sAPRIL: p = 0.807, sTACI:
p = 0.094, sBLyS: p = 0.116 and sBLyS-R: p = 0.701) in the
whole group. However, when patients were stratified by EULAR
clinical response, increasing sBCMA and sBLyS levels were found
in those classified as non-responders (Figure 3A). No differences
in baseline levels were observed between responders and
non-responders. Importantly, no differences in demographical
(age: p = 0.356 and gender: p = 0.580), clinical features
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FIGURE 2 | Cluster analysis of B-cell factors. Heatmap showing the
dendrogram classification of the clusters based on the serum levels of B-cell
factors and their decoy receptors (columns). Each row represents an
individual. Colors in the vertical left bar denoted RA patients (yellow) and HC
(red). Vertical right bar indicate the two clusters identified. Tiles are colored
based on serum levels, red and blue indicating low or high levels, respectively.
(RF positivity: p = 0.529, ACPA positivity: p = 0.928) or
treatments (glucocorticoid treatment: p = 0.836, glucocorticoid
dosage: p = 0.209 and methotrexate dosage: p = 0.371) were
found between responders and non-responders. Furthermore,
prescription regiments were followed up by the patients, thus
ruling out the possibility that adherence could be a confounding
factor.
The analysis of the mBLyS expression upon TNFα-blockade
revealed valuable insight into the relevance of different cell
populations. First, sBLyS serum levels after treatment were
positively correlated to mBLyS expression at baseline on
monocytes (r = 0.391, p = 0.009), neutrophils (r = 0.359, p =
0.019) and mDC (r = 0.294, p = 0.050), whereas no association
was observed with that of B-cells (r = 0.129, p = 0.405).
Interestingly, these differences seem to mirror those of the levels
of expression found among cell populations. On the other hand,
the analysis of the mBLyS baseline expression levels according to
the clinical response reinforced the differences observed among
cell populations: whereas higher mBLyS on B-cells at baseline
was associated with a good response, the opposite was observed
when monocytes and mDCs were analyzed (Figure 3B). Finally,
an integrative analysis including mBLyS expression on B-cells,
monocytes and mDC was performed. The three variables were
dichotomized using the Youden index (YI) of each distribution
from COR curves to maximize specificity and sensitivity [B-
cells: 36.25 (YI = 0.417), MO: 80.45 (YI = 0.708), and mDC:
61.70 (YI = 0.667)]. Next, the three categorized variables were
entered in a logistic regression analyses together with potential
confounders (age, gender and RF/ACPA positivity) to identify the
main predictor(s) of clinical response. Using theWald backwards
method, only the categorized mBLyS expression on monocytes
remained in the model as independent predictor (OR[95% CI]:
28.000[1.350, 108.591], p= 0.031).
Taken together, these results highlight a link between
increasing levels of B-cell factors and a poor clinical outcome
upon TNFα-blockade. A distinct contribution of different
immune cell populations can be expected, monocytes playing a
prominent effect.
DISCUSSION
B-cell activation represents a hallmark of RA pathogenesis.
Unveiling the main mechanisms and mediators underlying this
process is of outstanding relevance in RA and other rheumatic
conditions, not only from the perspective of basic science but
also to delineate potential therapeutic approaches. In the present
manuscript, we described the altered levels of B-cell related
factors and their decoy receptors in RA in relation to their
potential clinical relevance. To the best of our knowledge,
this is the first study providing a simultaneous analysis of
different B-cell factors in soluble and membrane-bound isoforms
together with the whole spectrum of their decoy receptors in
RA. Additionally, a thorough study of their clinical relevance to
treatment outcomes is prospectively addressed.
A major breakthrough of our study were the differences
observed between the very early and the established disease
stages. A clearly different role of the BLyS/BLyS-R axis was
observed between these disease stages. Increased levels of BLyS
in serum (20) and expression levels (21) were previously
reported in VERA, with some controversy results being published
elsewhere (22). However, our results went further by studying its
associations with its highly specific soluble receptor and related
activating factors, as well as prospectively analyzing its role as
a biomarker of clinical outcome. On the contrary, not only
sTACI was associated with disease activity in established RA,
but a distinct pattern of B-cell factors was observed in these
patients. These findings suggest that different pictures of B-cell
factors are related to B-cell activation along RA the course. BLyS
is mostly linked to naïve B-cell activation, whereas its role in
antigen-experienced B-cell subsets is debated (23, 24). On the
contrary, APRIL and BCMA govern the activation of thememory
B-cell subsets as well as plasma cell differentiation and survival
(25, 26). Importantly, APRIL supports plasma cell in the absence
of BLyS (27). Moreover, BLyS-R expression is dominant in B-
cells from germinal centers, whereas TACI and BCMA expression
are characteristic of memory and short-lived antigen-producing
cells (28). The association between APRIL and BCMA with
ACPA/RF positivity observed in our study supports this notion.
Then, it is likely that the very early stage of the disease could
be strongly BLyS-dependent, whereas a different pattern of B-
cell factors, mainly APRIL-dependent, underlie the chronic phase
of the disease. This finding may challenge a previous study by
Geng et al. (22), reporting elevated sBLyS levels in sero-negative
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TABLE 2 | Clinical and immunological features of RA patients depending on B-cell factors clusters.
Cluster I
(n = 72)
Cluster II
(n = 32)
p-value
DEMOGRAPHICAL FEATURES
Age, years; median (range) 53.95 (22.00–79.92) 55.33 (22.42–87.00) 0.714
Gender, f/m 59/13 26/6 0.933
DISEASE FEATURES
Disease duration, years; median (range) 3.12 (0.00–15.00) 3.98 (0.00–13.80) 0.937
Age at diagnosis, years; median (range) 49.37 (20.00–70.00) 49.29 (19.00–65.00) 0.743
Disease activity (DAS28) 3.75 (1.92) 4.05 (2.32) 0.729
Tender Joint Count 3.00 (7.00) 3.00 (2.00) 0.801
Swollen Joint Count 2.00 (5.00) 1.00 (5.00) 0.241
Patient Global Assessment (0-100) 48.00 (44.25) 40.00 (48.00) 0.142
ESR, mm/h 18.00 (21.25) 21.00 (40.50) 0.509
CRP, mg/l 2.07 (4.00) 2.65 (9.78) 0.281
HAQ (0-3) 1.00 (1.13) 1.00 (1.38) 0.837
RF (+), n (%) 36 (50.0) 24 (75.0) 0.008
ACPA (+), n (%) 39 (24.1) 28 (87.5) 0.006
Erosive disease, n (%) 26 (36.1) 14 (43.7) 0.562
TREATMENTS a, n (%)
Glucocorticoids 45 (72.5) 13 (54.1) 0.240
Methotrexate 47 (75.8) 18 (75.0) 0.938
TNFα blockers 20 (32.2) 12 (50.0) 0.003
Tocilizumab 1 (1.9) 2 (8.3) 0.179
CYTOKINES SERUM LEVELS, MEAN ± SD
TNFα, pg/ml 247.81 ± 188.80 428.62 ± 279.68 <0.001
IFNα, pg/ml 11.55 ± 42.59 59.38 ± 103.93 0.020
MIP1α, pg/ml 17.78 ± 27.97 47.89 ± 80.98 0.035
GM-CSF, pg/ml 31.61 ± 30.01 63.76 ± 47.69 <0.001
IFNg, pg/ml 7.10 ± 14.43 13.77 ± 22.40 0.154
IL-8, pg/ml 51.20 ± 31.65 61.87 ± 40.72 0.404
IL-10, pg/ml 3.75 ± 13.66 3.63 ± 4.95 0.138
IL-37, pg/ml 257.35 ± 671.87 1055.99 ± 1841.74 0.015
IFN SCORE, MEAN ± SD
IFN score 0.07 ± 0.81 0.63 ± 0.90 0.015
aTreatment usage was calculated as the number of patients using a given treatment among the number of patients receiving any treatment (cluster I: n= 61, cluster II: n= 24). Statistical
analyses with a p-value below 0.050 are highlighted in bold.
RA independently of disease duration. However, the lack of
information about the additional B-cell activating factors in their
study did not allow to a proper comparison between studies.
Taken together, these observations shed new light into the B-cell
factor network in RA and may provide a rationale for treatment
decision-making when considering B-cell factors as therapeutic
targets.
Furthermore, our data showed a pronounced elevation of B-
cell factors in RA, whereas their decoy receptors mostly remained
within the normal range. Interestingly, the degree of occupancy
of BLyS receptors in SLE has been related to disease activity (29).
Importantly, our study demonstrates comparable sBLyS serum
levels in RA and SLE patients. The decoy receptors efficiently
block the soluble and membrane-bound forms of the B-cell
factors (30, 31), hence suggesting that the analysis of the B-
cell factors alone can provide limited information. However,
the analysis of decoy receptors has been largely neglected in
previous studies in RA. Our findings delineate a picture of
elevated B-cell factors in RA with unchanged levels of its decoy
receptors, hence pointing toward a less efficient negative feedback
of the latter. This is supported by the findings on the ratio
between sBLyS and sBLyS-R in our study, which may represent
a surrogate marker of the degree of occupancy of sBLyS-
R. Although a pivotal role of BLyS-R in the development of
autoimmunity and antibody production was described in mice
models (32), it had not previously evaluated in human patients
until date.
Additionally, the analysis of the membrane expression of
BLyS confirmed that different cell populations may account
for the increased levels of B-cell factors in RA. Although
classically linked to B-cell activation, the expression of BLyS
and other B-cell related factors has been observed in other
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FIGURE 3 | B-cell related factors upon TNFα-blockade in RA patients. (A) Paired analyses of the changes in the serum levels of B-cell related factors at baseline (BL)
and post-treatment (PT) after TNFα-blockade in a subgroup of 13 RA patients prospectively followed. Patients were classified as responders or non-responders
according to EULAR criteria. Each dot represents an individual. Statistical analysis was performed by Wilcoxon test. (B) Analysis of the BLyS surface expression
(mBLyS) at baseline (BL) on B-cells, monocytes (MØ), neutrophils (NØ) and myeloid DC (mDC) after 3 months of TNFα-blockade. Patients were classified as
responders (R) or non-responders (NR). Boxes represent 25th and 75th percentiles, whereas whiskers represent minimum and maximum values. Differences were
assessed by Kruskal-Wallis with Dunn-Bonferroni tests for multiple comparisons tests. P-values shown correspond to those obtained in the multiple comparisons
tests.
cell populations, such as neutrophils and monocytes (9, 10).
However, whether this could be relevant to RA pathogenesis
and extended to other cell populations remained unknown.
The findings herein presented revealed a widespread BLyS
expression beyond the B-cell compartment in RA, mainly on
monocytes and mDCs subsets, linked to clinical outcomes. In
fact, the mBLyS upregulation was similar to that of observed
in SLE patients. More importantly, the membrane expression of
BLyS seemed to have different clinical relevance depending on
the cell population involved, especially concerning the clinical
response to TNFα-blockade. On the one hand, increased BLyS
expression on myeloid subsets was related to a poor clinical
outcome, and BLyS expression levels at baseline on monocytes
was positively correlated to sBLyS levels after treatment, which
was in turn associated with a poor clinical response. This is
especially relevant since sBLyS is the major contributor of its
biological effects compared to the membrane-bound isoform,
as evidenced in trans-well culture assays with B and myeloid
cells (4, 33), and orchestrates the macrophage and dendritic
cell-dependent regulation of human B-cell proliferation (34).
Importantly, previous studies from our group have highlighted
differences in BLyS mobilization in monocytes compared with
other cell populations (11). On the other hand, increased BLyS
on B-cells was found in RA patients exhibiting a good response.
It is important to note that BLyS has been reported to show a
protective effect in certain scenarios related to B-cell activation
(35, 36), and a regulatory function of APRIL (37), presumably
via a Breg-dependent mechanism (38), has been suggested in
APRIL transgene mice. Interestingly, other APRIL transgene
and knock out models showed yielded different conclusions
[reviewed in (4)]. Taken together, the cell populations producing
and reacting to BLyS emerge as key players to understand its
clinical relevance, hence adding another layer of complexity to
this scenario.
Our findings broaden the relevance of the B-cell factor
network by documenting its association with myeloid cell
subsets, key players of the innate immunity. In fact, severalinnate
immune mediators were found to be elevated in patients with
high levels of sAPRIL and sBCMA (cluster II), which may
orchestrate the crosstalk between B-cell and innate subsets.
Among them, the type I IFN must be remarked. Because of their
immune-activation capacities, type I IFN have been extensively
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studied in systemic autoimmune conditions (39). Although type
I IFN were known to prompt a B-cell over-activation, it was
only in recent years that a link between IFN and BLyS was
reported in different conditions (13, 40) and confirmed in vitro
(41). Also, a similar effect was reported for APRIL (42). Our
results showed for the first time an association between both
IFN signature and B-cell factors in RA. A similar association
was observed at the protein level with IFNα serum level,
hence strengthening this finding. Moreover, although the TLR
pathway had been associated with the sBCMA shedding from
plasmacytoid DC (43), our results went further by reporting
an association with other decoy receptors of the BLyS/APRIL
system. Interestingly, the association between the IFN score and
sBLyS-R and sTACI was dependent on the disease stage, which
is in line with the heterogeneity of the IFN score reported in
RA along the disease course (15), as well as with the differential
associations of sBLyS previously observed. In fact, not all the
IFN-responding genes are equally linked to BLyS [data not
shown and (44)]. Therefore, a detailed analysis of the IFN-
responding genes in relation to BLyS expression warrants further
studies.
B-cells are pivotal therapeutic targets in RA, as evidenced
by early studies with rituximab (45). However, rituximab
treatment does not affect all B-cell subsets and changes on B-
cell frequency and IgG levels do not always parallel clinical
response (2), thus underlining the involvement of additional
mediators. However, B-cell factors exhibit complex and mutual
mechanisms of regulation, with certain degree of overlap and
even redundancy, as observed in our study. Indeed, not all B-
cell factors are equally affected by rituximab treatment (46). The
differential effect of belimumab (which targets soluble BLyS) and
tabalumab (which targets both soluble and membrane-bound
isoforms) supports this notion. More importantly, B-cell factors
are usually present in serum in heteromeric isoforms whose
composition is thought to play a significant role (47, 48), and
the decoy receptors are known to effectively block heteromeric
complexes (48), although to a variable degree (49). Therefore,
a therapeutic approach solely based on a single B-cell factor
may not be appropriate in this scenario, as demonstrated by
the modest, albeit significant, the clinical effect of anti-BLyS
therapies in RA [reviewed in (16)], in contrast to SLE, where
BLyS plays a prominent pathogenic role. As a consequence,
additional mediators are thought to be differentially involved in
RA, hence bringing the attention to the B-cell factor network
in this conditions. This led to the development of a combined
approach to target both BLyS and APRIL (atacicept). The
growing list of biological therapies together with theirelevated
costs strongly stress the need for biomarkers to assist in patient
stratification to ensure cost-effectiveness of such treatments.
Recent results from AUGUST trials (I and II) revealed a clear
biological activity of this drug, whereas the clinical endpoint
was not achieved (50, 51), thus emphasizing the need of a
personalized approach to assist in patient stratification. In
this sense, we have conducted an unsupervised, hypothesis-
generating integrative approach to identify subsets of patients
based on their profiles of B-cell factors. Those patients with
increased levels of these factors can be considered as those
more likely to respond to such interventions. Our results
revealed that increased sAPRIL and sBCMA identify a subset
of patients with an increased prevalence of autoantibodies, and
a pronounced proinflammatory milieu despite being largely
treated with anti-TNFα drugs, which points to a poor response
to these agents, as confirmed in our prospective analysis.
Together with the increased expression of mBLyS observed
in RA patients, our results may provide a rationale for
decision-making in atacicept prescription. Not only by blocking
elevated APRIL serum levels but also by removing circulating
myeloid cells with increased mBLyS expression, atacicept could
represent a promising therapy in these patients. Of note, a
post-hoc analysis of the APRIL-SLE study demonstrated the
usefulness of BLyS and APRIL serum levels as biomarkers to
predict clinical response to atacicept (52), linked to a greater,
dose-dependent pharmacodynamics effect. Moreover, patients
with elevated levels of both APRIL and BLyS exhibited a
more severe disease, which is line with our findings in RA
patients.
In conclusion, our study demonstrates an upregulation of
B-cell factors in both serum and membrane-bound forms
in RA patients depending on their disease stage, together
with unchanged levels of their decoy receptors. Myeloid cell
populations seem to contribute to the BLyS overexpression in
RA. Moreover, sAPRIL and sBCMA serum levels identify a
subset of patients with a more severe disease and increased
prevalence of autoantibodies, probably linked to a B-cell over-
activation and immune-stimulatory status. Finally, poor response
to TNFα-blockade was associated with increasing B-cell factors.
Overall, an integrative approach of the network of B-cell factors
may assist in patient stratification. Finally, it is important to
consider that this work represents a proof-of-concept study
on the B-cell factors network and its clinical relevance in RA.
As such, a number of limitations must be remarked, like the
observational design and the reduced sample size of some
analyses. Further follow-up studies are needed to elucidate the
clinical benefit of these findings in the long-term. Also, separate
analyses on individual cell populations will shed new light
into the biological mechanisms underlying the findings herein
described.
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